Adoption of Innovative Approaches to Ensure Continuity of Quality TB Services During COVID-19 Pandemic in Lusaka and Livingstone, Zambia. (Telemedicine in TB)

NCT ID: NCT06883643

Last Updated: 2025-03-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

3318 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-04

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Following the negative impact of public health program services including TB services by the COVID-19 Pandemic in 2020, CIDRZ conducted a program evaluation for remote patient follow up for TB treatment and prevention through a differentiated service delivery model (DSD), offering clinical monitoring and psychosocial support while minimizing contact with the health facilities. The project was implemented between February 2022 to March 2023 and was funded through Centers for Disease Control and Prevention's COVID-19 Response International Task Force - CARES funding. While DSD models have been widely adopted in HIV programs , DSD is a relatively new and exciting approach for TB treatment and prevention programs.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

During the COVID-19 pandemic, government restrictions on movement decreased access to health care. Although DSD models have been widely adopted in HIV programs, this is a relatively new approach for TB programs. Zambia's NTLP has already changed policy to allow for such adaptations of service delivery, but these adaptations are not universally implemented and have not been evaluated at this time. This project aims to evaluate these DSD models for both TB treatment (Anti-TB Treatment ATT) and TPT using standardized indicators. To complement these DSD models, innovative approaches like digital (texting/SMS and phone) treatment support and remote monitoring of adverse events will be adopted using bi-directional SMS through use of the rapid pro system, a tool that allows medical information to be gathered and shared via a cell phone.

1. To implement TPT in 6MMD and ATT DSD models at 5 sites in Lusaka and Livingstone districts
2. To assess acceptability of TPT in 6MMD and ATT DSD models at implementation sties
3. To assess trends in TPT coverage and completion rates from pre-implementation through implementation periods using aggregate program performance data
4. To assess trends in ATT completion rates from pre-implementation through implementation periods using aggregate program performance data
5. To inform the Ministry of Health on a systematic approach for digital follow up and screening for TB and TPT RoCs aligned to MMD models of care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Focus of the Study is to Evaluate DSD Models for Both TB Treatment and TPT Usiing Key Performance Indicators

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Project evaluation
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TB treatment ARM

Beginning February 2022, we offered ATT via 2-month MMD during intensive and 4-month MMD during continuation phases.

In-clinic visits during 6-months of ATT were reduced from 7 under standard of care to 3 visits in DSD, while ensuring robust adherence and adverse event screening.

Remote monitoring consisted of structured SMS (months 1 to 5) and phone (week 2 and month 3) follow-up to assess adherence and screen for side effects. If SMS were not returned, a phone or home visit was triggered.

Group Type ACTIVE_COMPARATOR

Differentiated service delivery approach (DSD) in TB treatment and prevention.

Intervention Type BEHAVIORAL

Although DSD models have been widely adopted in HIV programs, DSD is a relatively new approach for TB programs because of an historical reliance on directly observed therapy (DOT) (6). DSD provides opportunities to improve health outcomes and reduce the burden of seeking care for people diagnosed with TB.

TPT DSD

Beginning February 2022, we offered TPT aligned to 6MMD ART model following standard of care processes with added support (See below).

Remote monitoring consisted of structured SMS (months 1 to 5) and phone (week 2 and month 3) follow-up to assess adherence and screen for side effects.

ROCs that did not respond to the SMS within 2 days were further contacted via phone and if not reachable a home visit was done.

ROCs that reported at least one side effect or more were followed up with virtual reviews by clinicians.

At enrollment ROCs reading language of preference was documented and the SMS was sent in their preferred language.

Group Type ACTIVE_COMPARATOR

Differentiated service delivery approach (DSD) in TB treatment and prevention.

Intervention Type BEHAVIORAL

Although DSD models have been widely adopted in HIV programs, DSD is a relatively new approach for TB programs because of an historical reliance on directly observed therapy (DOT) (6). DSD provides opportunities to improve health outcomes and reduce the burden of seeking care for people diagnosed with TB.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Differentiated service delivery approach (DSD) in TB treatment and prevention.

Although DSD models have been widely adopted in HIV programs, DSD is a relatively new approach for TB programs because of an historical reliance on directly observed therapy (DOT) (6). DSD provides opportunities to improve health outcomes and reduce the burden of seeking care for people diagnosed with TB.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

TB ARM

* All ROCs presenting to chest clinic for TB treatment between February 2022 and September 2022 were considered for inclusion if:

Diagnosed with TB (new cases or retreatment cases) 18 years and above Willing and able to provide consent Not pregnant or breastfeeding No MDR TB

TPT ARM

All ROCs presenting to the ART clinic between February 2022 and September 2022 were considered for inclusion if they were:

18 years or above virally supressed with no symptoms or diagnosis suggestive of TB on ART for more than 6 months on 6MMD Consented to participate in the project did not receive TPT in the last 3 years not pregnant or breastfeeding women not incarcerated

Exclusion Criteria

ATT ARM

* RoCs those TB diagnosis is not confirmed
* RoCs who are less than 18 years old
* RoCs not able to provide consent for program evaluation participation
* RoCs with MDR TB

TPT ARM

* RoCs with symptoms suggestive of TB, diagnosed or confirmed with TB diagnosis

* RoCs who received TPT in the last 3 years
* RoCs who are less than 18 years old
* RoCs not able to provide consent for program evaluation participation
* Pregnant and breastfeeding women
* Incarcerated persons
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ministry of Health, Zambia

OTHER_GOV

Sponsor Role collaborator

Centers for Disease Control and Prevention's COVID-19 Response International Task Force - CARES funding

UNKNOWN

Sponsor Role collaborator

Centre for Infectious Disease Research in Zambia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mwanza Wa Mwanza, MD

Role: STUDY_DIRECTOR

Centre for Infectious Disease Research in Zambia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Lusaka and Livingstone districts

Lusaka, Lusaka Province, Zambia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Zambia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Telemedicine in TB

Identifier Type: -

Identifier Source: org_study_id

NU2GGH002251

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.